Abstract: A medical device that includes a handle, a sheath extending from the handle, and a tool within the sheath and movable relative to the sheath. The handle includes an inner body and an outer body disposed over the inner body. The outer body is movable relative to the inner body. The handle includes a first actuator secured to the tool. The first actuator has an actuated state permitting movement of the tool relative to the sheath in response to moving the outer body relative to the inner body. The handle includes a second actuator secured to the sheath. The second actuator has an actuated state permitting movement of the sheath relative to the tool in response to moving the second actuator relative to the outer body. An unactuated state of the first actuator and an unactuated state of the second actuator prevents movement of the tool relative to the sheath.

Abstract: The present invention relates to a combination of a selective noradrenaline reuptake inhibitor (NRI) and a phospho-diesterase type 5 (PDEV) inhibitor. Such a combination is particularly useful in the treatment of pain.

Abstract: Use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a pain condition selected from neuropathic pain, nociceptive pain, cancer pain, back pain, inflammatory pain, musculo-skeletal disorders, visceral pain, pain from strains/sprains, post-operative pain, posttraumatic pain, burns, renal colic, acute pain, central nervous system trauma, head pain, and orofacial pain, is disclosed. Use of (S,S)-reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of pain in a patient refractory to an alpha-2-delta ligand, and use of (S,S)- or racemic reboxetine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use as a mental performance or mood enhancer, are also disclosed.

Abstract: Combinations comprising a) an inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) and b) an angiotensin II receptor antagonist are useful for treating hypertension.

Abstract: Combinations comprising a) an inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) inhibitor and b) an inhibitor of angiotensin converting enzyme (ACE) are useful for treating hypertension.

Abstract: The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula I wherein R1 is H or C1-6 alkyl, wherein R1 is attached to either N1 or N2; R2 is C1-6 alkyl optionally substituted by hydroxy or alkoxy; C3-7 cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het1 or Ar1; R3 is C1-6 alkyl optionally substituted by 1 or 2 groups independently selected from: Ar2; C3-7cycloalkyl optionally substituted by C1-6alkyl; OAr2; SAr2; NHC(O)C1-6 alkyl; het2; xanthene; and naphthalene.